Covid-19 vaccine Covovax, developed by US biotechnology company Novavax and produced by the Serum Institute of India, was granted Emergency Use Listing (EUL) by the World Health Organization (WHO), Faberco Life Sciences Inc. (Faberco), the local pharmaceutical company that has the rights to distribute the vaccine in the country announced on Monday.
“We welcome the approval from the WHO and are excited to finally bring this high-quality vaccine to the Philippines,” said Mr. Vinay Panemanglor, chairman of the Board of Directors of Faberco.
Such development will clear the way for the delivery of Covovax️ to the global Covax facility and countries like the Philippines and Indonesia.
The vaccine will carry the trademark Covovax in the Philippines.
The overall efficacy rate is 90.4 percent and 92.6 percent against variants of interest and concern, one of the highest among all vaccines approved for use in the country.
Covovax will be distributed in the Philippines by Faberco and Unilab.
“We are looking forward to fulfilling our commitments to bring Covovax to the Filipino people via the national and local government units, and private entities,” said Panemanglor.
He said that they are looking forward to helping the nation ease further into the next normal where Covid-19 is “expected to continue being a health issue worldwide.”
Faberco, a Philippine pharmaceutical organization, is focused on providing innovative, highly niche pharmaceutical products to both public and private health sectors.
It partnered with reputable international manufacturers who target product platforms and therapeutic categories to treat and prevent diseases which are of public health concern.
